<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>9706604</identifier>
<setSpec>0025-7753</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Casas, A</dc:author>
<dc:author>Iribarren, J A</dc:author>
<dc:author>Rodríguez Arrondo, F</dc:author>
<dc:author>Camino, X</dc:author>
<dc:author>Von Wichmann, M A</dc:author>
<dc:author>Arrizabalaga, J</dc:author>
<dc:description xml:lang="en">BACKGROUND Hypersensitivity reactions to rifampin are relatively uncommon, but they may result in cessation of therapeutic medications. PATIENTS AND METHODS We report our experience with oral desensitization protocol to rifampin in a group of 35 HIV-positive patients with mycobacterial disease who had some hypersensitivity reaction to this drug. RESULTS Adverse reactions with this protocol were few and easily treated. CONCLUSIONS Oral desensitization to rifampin is safe and effective, allowing some of these patients (60%) to reintroduce the drug and to reduce the time of treatment.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:date>1998 Jun 27 </dc:date>
<dc:title xml:lang="es">Utilidad de la desensibilización a rifampicina en el tratamiento de enfermedades producidas por micobacterias en pacientes con SIDA.</dc:title>
<dc:title xml:lang="en">[The usefulness of the desensitization to rifampin in the treatment of mycobacterial disease in patients with AIDS].</dc:title>
<dc:publisher>Medicina clinica</dc:publisher>
</metadata>
</record>
</pubmed-document>
